0% Complete
صفحه اصلی
/
4th international edition and 13th Iranian Conference on Bioinformatics
New inhibitors of the Toxoplasmosis by in-silico drug repurposing
نویسندگان :
Milad Jaberi
1
Masoud Aliyar
2
Mosleh Kadkhodamohammadi
3
Parva Karimimousivandi
4
1- Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
2- Faculty of Science, Golestan university, Shahid Beheshti Street, Gorgan, Golestan province, Iran
3- 2. Faculty of Medicine, Central Building, Tabriz University of Medical Sciences, University Street, Tabriz, Iran
4- 3. Friedrich Schiller University Jena, faculty of sciences, Fürstengraben 1, 07743 Jena, Germany
کلمات کلیدی :
Toxoplasma Gondii،Drug repurposing،Docking،Molecular Dynamics
چکیده :
Introduction: The common treatment for toxoplasmosis was pyrimethamine. It has been noticed in recent years that this parasite becomes resistant to this treatment and it thus needs immediate alternative therapies. Materials and Methods: In this study, using drug re-purposing and in silico methods we tried to make selective treatment by inhibiting the Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii which does not exist in mammalians. We screened the FDA approved drugs by molecular docking and, after ranking them by their binding energies and inspecting the top scoring ones, we selected Cefpiramide, Ceftriaxone and Cefotiam as the hit compounds. Afterwards, we used molecular dynamic simulations to evaluate the hit compounds in a much more realistic environment. Results: Through analyzing the results, we have found that all of the hit compounds are effective and can be strongly bound to the active site of the protein. They may therefore be potential candidates for the inhibition of Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii. Conclusion: Given that the predicted compounds are FDA approved drugs, their toxicity profiles are established and their potentially predicted use can be evaluated in clinical trials.
لیست مقالات
لیست مقالات بایگانی شده
Investigation of antiviral potency of fungal metabolites against Hepatitis C NS5B
Zohreh Sahhaf Razavi - Ali Ramazani - Armin Zarei
Reduced PINK1 Expression in Bladder Cancer: Insights into Autophagy Dysregulation and Therapeutic Potential
Shayan Jahangirzadeh - Mehdi Asghari Vostakolaei - Asadollah Asadi - Masoumeh Valipour
Definition of SARS-CoV-2 proteins antigenicity by computational immunology
Fatemeh Hajighasemi - Atefeh Shirkavand
BIRC5: The Silent Architect of Tumor Persistence and Senescence in Hepatocellular Carcinoma
Amirhosein Farrokhzad - Maryam Kaboli - Elahe Hoseinnia - Elham Rismani - Massoud Vosough
Enhancing NAFLD Diagnosis with AI: Insights from the Persian Fasa Cohort Through Advanced Machine Learning Techniques
Marzie Shadpirouz - Mohammad Reza Zabihi - Zahra Salehi - Kiarash Zare - Mohammad Mehdi Naghizadeh - Kaveh Kavousi
Bioinformatics studies on S35K mutation on Mnemiopsin 2 photoprotein
ََAmirReza Mohammadi - Vahab Jafarian - Fatemeh Khatami
Development of Novel Cellulose Crystal-Hyaluronic Acid Anti-Cancer Carriers for Targeting
Yeganeh Abbasian Bajgiran - Maryam Azimzadeh Irani
3D-QSAR Modeling on 2-Pyrimidine Carbohydrazides as Utrophin Modulators for the Treatment of Duchenne Muscular Dystrophy by Combining CoMFA, CoMSIA, and Molecular Docking Studies
Reza Mahmoudzadeh Laki - Eslam Pourbasheer
Distribution and Allelic Diversity of Outer Membrane Proteins in Helicobacter pylori: Implications for Vaccine Development and Therapeutic Approach
Mohammadreza Najafi Disfani - Mahyar Abdi - Sarvin Rezvani Bafroyeh - SeyedehRomina Lavasani - Parastoo Saniee
AI-Driven Discovery of Novel AChE Inhibitors for Alzheimer's Disease Treatment: Model Development, Molecular Docking, and MD Simulation
Ahmad Ebadi - Fatemeh Noori
ثمین همایش، سامانه مدیریت کنفرانس ها و جشنواره ها - نگارش 40.4.1